Your session is about to expire
What is Mayzent
SiponimodThe Generic name of this drug
Treatment SummarySiponimod (also known as Mayzent) is a medication prescribed for the treatment of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. MS is an autoimmune disorder that affects the central nervous system, causing inflammation, fatigue, vision issues, mobility problems, and more. Siponimod is a sphingosine-1-phosphate (S1P) receptor modulator that works to reduce inflammation in the central nervous system. It is most commonly prescribed to adults aged 20-40, who are the most likely to
Mayzentis the brand name
Mayzent Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Mayzent
Siponimod
2019
3
Effectiveness
How Mayzent Affects Patients**Effects on the Immune System:** Siponimod causes a decrease in the number of lymphocytes in the blood within 6 hours of taking it. This reduces inflammation associated with multiple sclerosis. The decreased number of lymphocytes usually returns to normal within 10 days of stopping the drug. **Effects on the Heart:** Taking siponimod can temporarily lower heart rate and cause changes in heart rhythm. This usually occurs within 6 hours of taking the drug, but it does not affect heart rate during exercise or other activities. **Effects on Lungs:** Siponimod may
How Mayzent works in the bodyMultiple Sclerosis is caused by inflammation in the brain and spinal cord. This inflammation is caused by immune cells, such as B lymphocytes, and the chemicals they produce. Siponimod is a drug that works by blocking the release of lymphocytes from the lymph nodes. This reduces the number of lymphocytes in the body and prevents them from entering the central nervous system, which reduces the inflammation associated with Multiple Sclerosis. It is not yet known exactly how this drug works, but it is believed to be related to its ability to block the release of lymphocytes.
When to interrupt dosage
The suggested dosage of Mayzent is contingent upon the determined condition. The measure of dosage fluctuates, correlating to the technique of delivery (e.g. Tablet, film coated - Oral or Tablet - Oral) specified in the table beneath.Condition
Dosage
Administration
Multiple Sclerosis
, 2.0 mg, 0.25 mg, 1.0 mg
Tablet, film coated - Oral, Oral, Tablet, film coated, , Tablet - Oral, Tablet
Warnings
Mayzent ContraindicationsCondition
Risk Level
Notes
third degree AV block
Do Not Combine
Patients with a CYP2C9*3/*3 genotype
Do Not Combine
Heart Decompensation
Do Not Combine
Active infection
Do Not Combine
Cerebrovascular accident
Do Not Combine
Myocardial Infarction
Do Not Combine
Sick Sinus Syndrome
Do Not Combine
Atrioventricular Block
Do Not Combine
Transient Ischemic Attack (TIA) in the last 6 months
Do Not Combine
Unstable angina pectoris in the past 6 months
Do Not Combine
Heart failure
Do Not Combine
Common Mayzent Drug Interactions
Drug Name
Risk Level
Description
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Siponimod is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Acteoside
Major
The risk or severity of adverse effects can be increased when Siponimod is combined with Acteoside.
Adenovirus type 7 vaccine live
Major
The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Siponimod.
Anthrax vaccine
Major
The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Siponimod.
BCG vaccine
Major
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Siponimod.
Mayzent Toxicity & Overdose RiskCarcinogenesis: Siponimod has been shown to increase the risk of cancer in mice and rats, with higher doses having a greater effect. The lowest dose tested is five times the recommended human dose.
Mutagenesis: Tests have shown that siponimod does not cause changes in DNA or chromosomes.
Impairment of Fertility: Male rats given siponimod before and during mating had a longer time before mating and lower number of viable fetuses. Female rats given the drug had no effects on fertility up to the highest dose.
Mayzent Novel Uses: Which Conditions Have a Clinical Trial Featuring Mayzent?
A total of 25 active clinical trials are examining the potential of Mayzent to treat Multiple Sclerosis.Condition
Clinical Trials
Trial Phases
Multiple Sclerosis
21 Actively Recruiting
Phase 3, Phase 2, Phase 4, Phase 1
Patient Q&A Section about mayzent
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.What are the side effects of Mayzent?
"Headache, increase in blood levels of liver enzymes, falls, swelling in hands, feet, joints, or face, decreased heart rate, nausea, dizziness, and diarrhea have all been reported."
Answered by AI
What is Mayzent used for?
"Mayzent is approved by the FDA for treating relapsing forms of multiple sclerosis, which include clinically isolated syndrome, relapsing-remitting disease (RRMS), and active secondary progressive disease (SPMS with relapses)."
Answered by AI
Can Mayzent improve MS?
"Mayzent is an effective medication to treat relapsing forms of MS and CIS, reducing relapse rates by 55% more than placebo in a clinical trial of people with active SPMS."
Answered by AI
How quickly does Mayzent work?
"In Phase III clinical trials, Mayzent was shown to significantly lower disease progression in people with SPMS by 21% at 3 months. However, the length of time patients stayed in the study varied greatly, with a median study duration of 21 months but ranging from 1 day to 37 months."
Answered by AI